| Biomarker ID | 1002 |
| PMID | 23059047 |
| Year | 2012 |
| Biomarker | ABL2+SEMA4D+ITGAL+C1QA+TIMP1+CDKN1A |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Blood |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: Testing: (2·3, 95% CI 1·39–3·70) |
| Effect on Pathways | NA |
| Experiment | low-risk group Vs high-risk group |
| Type of Biomarker | Prognostic |
| Cohort | Patients with castration-resistant prostate cancer (n=62) were used as a training set, and 140 patients with castration-resistant prostate cancer in a validation set |
| Senstivity | NA |
| Specificity | NA |
| AUC | Training: 0·90 [95% CI 0·78–0·96] |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | quantitative PCR |
| Clinical | NA |
| Remarks | low-risk group with a median survival of more than 34·9 months (median survival was not reached) and a high-risk group with a median survival of 7·8 months; Low risk: 2×ABL2+SEMA4D+ITGAL –C1QA–TIMP1–CDKN1A<21.21; High Risk: 2×ABL2+SEMA4D+ITGAL –C1QA–TIMP1–CDKN1A>21.21 |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | ABL2, SEMA4D, ITGAL, C1QA, TIMP1, CDKN1A |